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Abstract
Background: Bladder cancer (BC) has the highest lifetime treatment costs per patient of all cancers. The objective
of this study was to characterize the use of health-care services and costs associated with BC among patients who
underwent radical cystectomy (RC) in the province of Quebec.
Methods: We conducted a descriptive study in a retrospective cohort of patients who underwent RC for BC
between 2000 and 2009. Data was obtained from two health administrative databases (RAMQ and ISQ). We
calculated average costs per patient and total costs in 2014 Canadian dollars for the following components of costs:
1) Pre-surgery costs (pre and post-urologist consultations, urologist consultations, cystoscopies, TURBTs, imaging
procedures); 2) Costs of radical cystectomy and 3) Post-surgery costs (urologist consultations, post-operative
consultations, medical oncologist consultations, imaging procedures and post-operative complication
management). ARIMA models were used to evaluate trends in average costs per patient over the study period.
Results: Among 2759 patients included in the study (75 % men), average pre-surgery costs, RC costs, and
post-surgery costs were estimated at 3762$, 18979$ and 4770$, respectively. RC cost was responsible for 69 % of
total costs, followed by post-operative consultations (7.8 %), post-operative complications and TURBTs (6 % of
total costs, each). Academic hospitals performed RC at a lower average cost, compared to community hospitals
(difference of $1000, p < .0001). A decreased trend in post-surgery costs was detected in the year 2009.
Conclusions: Costs of RC, TURBT, consultations and post-operative complications were the most important
economic components of total RC cost per patient in Quebec. Academic hospitals performed RC at a lower cost,
compared to community hospitals.
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Background
Bladder cancer (BC) has the highest lifetime treatment
costs per patient of all cancers, from diagnosis to death
[1, 2]. Perioperative and post-operative complications,
high recurrence rates, intensive surveillance strategies,
and expensive treatment costs are the key contributors
to the economic and health-services burden of this dis-
ease [3]. BC is the second most prevalent urological
cancer worldwide and the fifth most common diag-
nosed malignancy in Canada, with 8000 incident cases
and 2200 deaths expected for 2014 [4]. In the USA, 74
690 new cases and 15 580 deaths from BC are esti-
mated for this year [5]. A quarter of patients present
with muscle invasive BC, and about half of these indi-
viduals have occult distant metastases at the time of
presentation [3]. Transurethral resection of the bladder
tumor (TURBT) is a diagnostic and therapeutic inter-
vention in cases of superficial disease, while muscle in-
vasive bladder cancer often requires radical cystectomy
(RC) [6]. Epidemiologic trends, aging and evolving
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population demographics along with technological ad-
vances in endoscopy, diagnostic and surgical technique
will make the management of patients with bladder
cancer in the near future a more substantial economic
challenge [7, 8]. There is a lack of studies on the trajec-
tories of BC patients in the continuum of care with re-
spect to costs and the use of medical services [8].
Therefore, the objective of the present study was to de-
scribe health-care utilization and associated costs
among patients who underwent RC for BC in the prov-




We conducted a descriptive study analyzing health-care
services utilization and costs associated with BC in a
retrospective cohort of patients who underwent radical
cystectomy in Quebec between the years 2000 and 2009.
Data source
The cohort was built with the linkage of two provincial
health administrative databases: the medical billing re-
cords database of the Régie de l’assurance maladie du
Québec (RAMQ), and the Fichier des évenements démo-
graphiques de l’Institut de la statistique du Québec
(ISQ). The RAMQ is the government body that adminis-
ters healthcare provision in the province. All healthcare
services are recorded in the RAMQ administrative data-
bases and its associated claims files. The RAMQ claim
file provides information on medical services dispensed
to all Quebec residents (information on physician-based
ICD-9 diagnostic codes, act codes for therapeutic proce-
dures, their calendar dates and associated costs, charac-
teristics of the patient, health care providers and hospital
facilities). The ISQ administers the Fichier des événe-
ments démographiques which provides vital status data.
The linkage between RAMQ and ISQ data is possible
using a patients’ anonymous identifier (generated from
the Numéro d’assurance maladie - NAM, which is a
unique identifier for all legal residents of Quebec). The
use of the data was approved by the Comission de l’acces
a l’information (CAI) of Quebec. Ethics approval was
obtained from the Research Ethics Board of the McGill
University Health Centre.
Study population
Patients were selected from January 1st 2000 to Septem-
ber 30th 2009. We excluded subjects aged less than
40 years-old (the age cut-off point for micro-hematuria
workup in Canada) [9]. The index date is the date on
which each patient entered into the cohort (calendar
date of RC).
Health-care services utilization
We identified health-care services utilization for pa-
tients who underwent RC for BC cancer during the
4 months period before RC. The 4 months’ time frame
was adopted to assure that all medical services con-
sumed by patients were associated to RC for BC. We
identified the following components of health-care
utilization: 1) Pre-surgery period (pre-and post-
urologist consultations, urologist consultations, cystos-
copies, TURBTs, pathology and imaging procedures), 2)
Surgical period (RC), and 3) Post-surgery period (post-
operative urologist, medical oncologist, and other con-
sultations, and imaging procedures). Post-surgery
health services were determined up to one year after
surgery.
Cost assignments
Analogously to the time frame adopted for the identifi-
cation of health-care services, we calculated average
costs per patient and total costs for the following com-
ponents of costs on the continuum of care for BC : 1)
Pre-surgery costs (cost of pre-urologist consultations,
cost of post-urologist consultations, cost of urologist
consultations, costs of cystoscopies, costs of TURBTs,
costs of pathologic and imaging procedures; 2) Costs of
RC, and 3) Post-surgery costs (costs of urologist con-
sultations, costs of post-operative consultations, costs
of medical oncologist consultations, costs of imaging
procedures and costs of post-operative complications
management). The unit cost of each medical service for
consultations and imaging procedures was documented
from the RAMQ’s list of medical procedures act codes
approved for physician reimbursement fees in Quebec
[10, 11]. We did not include costs associated to equip-
ment and maintenance when computing costs for im-
aging procedures. When applicable, average and total
costs for cystoscopy, TURBT and RC included estima-
tion of hospitalization costs, pathology reports, urine
cytology, anesthetist fees and surgical cardio-pulmonary
monitoring. We assumed that each cystoscopy gener-
ates one urine cytology report; each TURBT leads to a
same-day hospitalization stay and 1 pathology report,
and each RC leads to 7 days hospitalization and 1 path-
ology report. Post-operative complications were identi-
fied by means of RAMQ procedure flash act codes, as
described in previous work [12]. Hospitalization and
pathology costs were estimated from the Ministere de
la Sante et des Services Sociaux (MSSS) du Quebec and
the McGill University Health Centre administration, re-
spectively [13, 14]. The unit costs and sources are pre-
sented in Table 1. All costs were assigned in Canadian
dollars and were estimated from the 2014 Quebec’s
public healthcare system perspective.
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Covariates
We analysed BC-associated costs across two groups of
variables: 1) Patient-related variables: age (four categories:
less than 60, 60–69, 70–75, more than 75 years) and gen-
der (dichotomous); and 2) Health-care services related
variables: hospital facility where RC was performed, hospi-
tals hosting an urology teaching program (dichotomous),
surgeons’ annual RC case load (three categories: surgeons
who perform less than 3 RC/year, surgeons who perform
between 3–9 RC per year and surgeons who perform
more than 9 RC/year), geo-administrative region where
RC was performed (4 regions, grouped A to D) and calen-
dar date of RC. Geo-administrative division is based on
the MSSS’s Academic Integrated Network of Health which
divides the province of Quebec into four regions accord-
ing to provision of medical services and university
affiliation [15].
Statistical analyses
Demographic characteristics, age and gender-specific in-
formation of the study population was retrieved. Descrip-
tive statistical analyses, including mean, median,
standard deviation (SD) and range of costs were calcu-
lated, along with patient’s units of medical services re-
lated to each component of costs. Normality of data
distribution was analysed by the Shapiro–Wilk test.
Comparisons of average costs between groups were per-
formed by t-tests and ANOVA tests, when applicable.
We used autoregressive integrated moving average
(ARIMA) models to evaluate trends in average total costs
per patient, average radical cystectomy costs per patient
and post-surgery costs per patient. We analysed differ-
ences between observed and forecasted average costs per
patient over 117-month periods ranging from January
2000 to September 2009. Cut-off points for comparison
between observed and forecasted values were established
after seasonal trends inspection of the time series plot for
Table 1 Costs associated with bladder cancer: Cost
Components and Unit cost. Time horizon: from 4 months
prior to radical cystectomy until 1 year after surgerya
Procedure Unit costb Source
PRE-SURGERY
Pre-urologist consultations
• Physician fees $ 50 Bladder cancer cohort
Range: $ 15.20 – $ 94.4
Post-urologist consultations
• Physician fees $ 50 Bladder cancer cohort
Range: $ 15.20 – $ 94.4
Urologist consultations
• Physician fees $ 40 Bladder cancer cohort
Range: $16.9 – 45.6
Cystoscopies
• Physician fees $ 50.9 RAMQ reimbursement
act code list (10,11)
• Procedure fees $ 192.3 Quebec MSSS (14)
• Urinary cytology $ 87 MUHC administration
TURBT
• Physician fees $ 208 RAMQ reimbursement
act code list (10,11)
• Hospitalization $ 1371 Quebec MSSS (14)
• Anesthesia physician
fees
$ 150 RAMQ reimbursement
act code list (10,11)
• Pathology report $ 40 MUHC administration
Imaging
• Physician fees $ 45 Bladder cancer cohort
Range: $ 16.5 - $200
RADICAL
CYSTECTOMY
• Physician fees $ 1 880 RAMQ reimbursement
act code list (10,11)
• Hospitalization $ 14 855 Quebec MSSS (14)
• Anesthesia physician
fees
$ 1 160 RAMQ reimbursement
act code list (10,11)
• Pathology report $ 450 MUHC administration
POST-SURGERY
Post-operative consultations
• Physician fees $ 50 Bladder cancer cohort
Range: $ 15.20 – $ 94.4
Post-operative urologist
consultations
• Physician fees $ 40 Bladder cancer cohort
Range: $16.9 – 45.6
Post-operative medical
oncologist consultations
• Physician fees $ 39 Bladder cancer cohort
Table 1 Costs associated with bladder cancer: Cost
Components and Unit cost. Time horizon: from 4 months
prior to radical cystectomy until 1 year after surgerya (Continued)
Range: $ 16.9 - $ 98
Post-operative imaging
• Physician fees $ 45 Bladder cancer cohort
Range: $ 16.5 - $200
Post-operative
complications
• Physician fees $ 550 Bladder cancer cohort
Range: $ 61.5 - $ 1184
• Hospitalization $ 1371 Quebec MSSS (14)
aCosts are shown in 2014 Canadian dollars
bPhysician fees’ unit costs for consultations and imaging are expressed as
average of unit cost according to each act code for reimbursement to
different specialties and imaging procedures
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each component of cost. Stationarity was assessed using
the autocorrelation function and the augmented Dickey
Fuller test. The autocorrelation, partial autocorrelation,
and inverse autocorrelation graphic functions were used
to model parameter appropriateness and seasonality. The
presence of white noise was assessed by examining the
autocorrelation at various lags using the Lung-Box chi
squared test. All analyses were two-sided with p ≤ 0.05
being considered significant. SAS 9.3 (SAS Institute Inc.,
Cary, NC, USA) was used to conduct the calculations.
Results
Characteristics of the study cohort and the health-care
system
Baseline characteristics of the cohort are summarized
in Table 2. We analyzed a cohort formed by 2759 pa-
tients who underwent RC for BC and with medical ser-
vices data available for the four months period before
RC (75 % were men). Approximately 30 % of patients
had post-operative complications. A total of 1355 pa-
tients (49 %) died during the study time period. Mean
and median follow-up of the cohort was 34 months
(standard deviation: 32 months) and 21.6 months
(range: 1 day-118 months), respectively. The estimated
overall 5-year survival rate was 46 %. During the study
period, RCs were performed by 122 surgeons in 42 hos-
pitals across the province. A total of 42 % of surgeries
were performed in a hospital hosting a urology training
program, whereas 43 % of procedures were performed
in hospitals with an annual case load of <10 RCs per
year. Surgeons with an annual RC case load of <3 RCs
per year were responsible for 58 % of RCs.
Health care services utilization and costs associated with
bladder cancer: pre and post-RC operative period
Average costs per patient and mean units of medical ser-
vices for each component are summarized in Table 3.
Figure 1, Fig. 2(a) and (b) illustrate the weighted average of
cost components for the pre and post-operative periods,
and costs according to patient’s gender and age, respect-
ively. Patients had a mean of 4.7 consultations with other
specialists before their first urologist visit (average costs of
pre-urologist consultations per patient: 1006 $). Mean
number of urologist consultations and TURBTs in the four
months before RC was 4.7 and 1.2 respectively. The average
cost of TURBT was the most significant component of
costs during the pre-operative period (2159 $), representing
40 % of total average costs before surgery. Patients tended
to have more expensive post-operative urologist consulta-
tions compared to the pre-operative period (average cost of
437 $ per patient in the post-operative period compared to
162 $ in the pre-operative period). Imaging procedures
were also used more frequently and at a higher cost after
surgery (4.5 post-operative imaging procedures per patient
with an average cost of 395 $). No significant differences
were observed for these components of costs according to
gender (Fig. 2(a)). On the other hand, older patients tended
to have higher pre and post-operative costs (Fig. 2(b)).
Cost of radical cystectomy
Cost of RC is shown in Table 3, and graphically illus-
trated in Figs. 3((a) and (b)). Average cost of surgery per
patient was estimated at 18 979 $. Surgery was 207 $
more expensive in men compared to women (Fig. 2(a),
p < .0001), and more costly in older patients (19 032 $
Fig. 2(b), p = 0.0002). Region A was the only administra-
tive region with hospitals performing RC at a cost higher
than the average (19 329 $, Fig. 3(a), p < .0001). Hospi-
tals hosting a urology training program performed RC at
an average of 1000 $ less expensive (at 5 %), compared
to community hospitals (Fig. 3(b), p < .0001).
Table 2 Characteristics of the study population
Total (2759, 100 %)
Patient-related variables
Gender
Male 2091 (75.8 %)
Female 668 (24.2 %)
Age
Less than 60 years-old 643 (23.3 %)
Between 60–69 years-old 828 (30 %)
Between 70–75 years-old 557 (20.2 %)
More than 75 years-old 731 (26.5 %)
Post-operative complications
Yes 849 (30.7 %)
No 1910 (69.3 %)
Overall mortality 1355 (49.1 %)
5 years overall survival 46 %
Health system characteristics
RUIS-MSSS region where surgery was performed
Region A 1342 (48.6 %)
Region B 632 (23 %)
Region C 563 (20.4 %)
Region D 222 (8 %)
Surgery in a urology teaching hospital 1172 (42.48 %)
Hospital annual RC case load
Less than 10 RCs per year 1184 (42.9 %)
Between 10–25 RCs per year 934 (33.8 %)
More than 25 RCs per year 641 (23.3 %)
Surgeon annual RC case load
Less than 3 RCs per year 1621 (58.7 %)
Between 3–9 RCs per year 814 (29.6 %)
More than 9 RCs per year 324 (11.7 %)
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Table 3 Average costs per patient attributable to the health continuum of care for bladder cancer. (Time window: from four months before radical cystectomy up to 1 year
post surgery. Costs shown in Canadian dollars)
N (%) Mean and standard deviation
(SD) of service units per patient
Median (IQR) service
units per patient
Mean and standard deviation (SD) of
costs per patient (Canadian dollars)
Median and range of costs
per patient (Canadian dollars)








2155 (78.1 %) Mean: 4.3 (SD: 4.2) Median: 3 (IQR:2–5) Mean: 935 (1038) Median: 523 (6.2-6000)
Urologist consultations 2731 (99 %) Mean: 4.7 (SD: 3.8) Median: 4 (IQR:3–6) Mean: 162 (80) Median: 140 (17–1959)
Cystoscopies 1896 (68.7 %) Mean: 1.19 (SD: 0.46) Median: 1 (IQR: 1–1) Mean: 323 (37) Median: 273 (273–870)
TURBTs 2058 (74.6 %) Mean: 1.15 (SD: 0.39) Median: 1 (IQR:1–1) Mean: 2159 (773) Median: 1911 (1703–4115)
Imaging (physician fees) 2532 (91.7 %) Mean: 2.5 (SD: 1.55) Median: 2 (IQR: 1–3) Mean: 242 (154) Median: 205 (12-1397
RADICAL CYSTECTOMY COSTS
Radical cystectomy 2759 (100 %) 1 1 Mean: 18 979 (1168) Median: 18 440 (16 005–25 684)
POST-SURGERY COSTS
Post-operative urologist consultations 2606 (94.5 %) Mean: 4.7 (SD: 5.17) Median: 3 (IQR: 2–6) Mean: 437 (635) Median: 196 (17–9479)
Post-operative consultations
(all specialties confounded, excluding
urologists and medical oncologists)
2742 (99.4 %) Mean: 32 (SD: 29) Median: 24 (IQR: 13–41) Mean: 2232 (2275) Median: 1464 (17–27057)
Post-operative medical oncologist consultations 809 (29.3 %) Mean: 10 (SD: 10.9) Median: 7 (IQR: 2–14) Mean: 526 (579) Median: 346 (14.75-3860)
Post-operative imaging (physician fees) 2535 (92.1 %) Mean: 4.5 (SD: 3.3) Median: 4 (IQR: 2–6) Mean: 395 (307) Median: 311 (12.3-2845)














Cost of post-operative complications
Cost of post-operative complications is shown in Table 3,
and graphically illustrated in Fig. 1, Fig. (4(a) and (b)).
Average cost of post-operative complications was the most
significant component of costs after surgery. Among pa-
tients who had these complications (30 %); patients had a
mean of 3.7 complications at an average cost of 5703 $
per patient. An extreme variation in the average costs per
patient was identified among hospitals across the prov-
ince, with hospitals of the Region D having the higher
average costs per patient (6015 $, compared to 5782 $ in
region A, 5530 $ in region B and 5610 $ in region C).
Hospitals hosting a urology teaching program showed a
non-significant lower average costs per patient for post-
operative complications, compared to community hospi-
tals (5582 $ and 5811 $, respectively).
Total costs of bladder cancer
Units of health services utilization and its total costs are
described in Table 4. Table 5 displays average and total RC
costs per patient, average and total pre-surgery cost per
patient and average and total post-surgery costs per pa-
tient stratified by year. Percentages of each component of
costs are graphically represented in Fig. 5. Over 10 years,
total costs of BC requiring radical cystectomy to the pro-
vincial health system was estimated at 75 563 893 $. Dur-
ing the study period, 2759 RCs were performed at a cost
of 52 372 057 $, representing 69 % of total costs of RC for
BC (Fig. 5). Post-operative consultations was the second
most expensive component (5 594 774 $. 7 % of total
costs) followed by post-operative complications (4 356
127 $, 6 % of BC total costs) and TURBTs (4 340 247 $,
6 % of total costs).
Time series and trend analyses
Figure 6 demonstrates time trends in average RC costs
per patient (A), average post-operative costs per patient
(B) and average total costs per patient (C) over the
117 month period between January 2000 and September
2009. Trends in average RC costs per month were de-
scribed by an ARIMA (2,1,1) model, with comparison
between observed and forecasted values modeled from
period 72 (January 2006), and forecasted up to period
117. Period 72 was chosen as a cut-off point because of
an apparent decreasing trend for this component of cost
starting from this period, as inspected at the time series
plot for this component of cost. No significant trend was
detected over time (Fig. 6(a)). On the other hand, we ob-
served a non-significant decreased trend during the year
2009 for the average of post-operative and total costs
per month, as described by two independent ARIMA
(1,1,0) models (Fig. 6(b) and (c)). A significant difference
of −5175 $ was detected between observed and pre-
dicted values of average post-operative costs in Septem-
ber 2009. In addition, a significant difference of −6000 $
was detected between observed and predicted average
total costs in September 2009. These decreases in costs
are attributed to a lower average cost of medical
Fig 1 Weighted average costs per patient attributable to the health continuum of care for bladder cancer
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Fig 2 Average pre and post-surgery costs, radical cystectomy and total costs according to patient’s gender (a) and age (b)
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Fig 3 Variations for average RC costs among hospitals across the province (a), and according to the presence of a urology teaching program (b)
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Fig. 4 Variations for average post-operative complications costs among hospitals across the province (a), and according to the presence of a
urology teaching program (b)
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consultations, compared to the mean for the entire study
period (Table 6). Stationarity analyses did not reveal any
time trend for the number of RC performed during each
month period, as well as for average pre-operative costs
per month.
Discussion
Previous studies have shown that radical cystectomy ac-
counts for the largest proportion of payments for bladder
cancer care; these costs showing great variability depend-
ing on the country [8, 16]. For example, average European
RC reimbursement costs in US dollars, (including hospi-
talizations costs and medical fees) varies from 5684 $ in
the United Kingdom, 9697 $ in France, 10 932 $ in
Belgium and 15 419 $ in Germany [7]. The cost of radical
cystectomy including lymphadenectomy and urinary di-
version at an academic hospital center in the USA was cal-
culated at 30 000 $ with most costs attributed to the
operating room and hospital stay [8]. In our study, RC
costs in Quebec lies between the estimates for Europe and
North America and represents 69 % of average costs of
bladder cancer requiring RC from diagnosis to one year
after surgery. This variation in surgery costs estimates
across countries is probably attributable to differences in
practices such as inpatient or outpatient care, duration of
hospitalization, methods of calculating costs and billing,
disease incidence, and the type of surgical procedure
(open, laparoscopic, or robot-assisted) [17].
Our findings also showed variations in costs for RC
within the provincial health-care system. Costs of sur-
gery varied across patient gender, patient age group, and
administrative region where RC was performed. Cost
variations were also detected across individual hospitals,
with the majority of facilities performing surgeries at a
higher than the average cost. Although these disparities
were relatively small, we detected a significant 1000 $
greater average cost per patient between community
hospitals compared to hospitals hosting a urology train-
ing program. Given that hospitalization and operation
room costs were estimated with the provincial ministry
of health’s data and attributed equally to all surgical pro-
cedures in all hospitals in our cohort, we believe that
this difference is caused by the greater amount of med-
ical fees reimbursed to physicians in community hospi-
tals. Indeed, we found that among community hospitals,
surgeries are performed by an average of 2.9 surgeons
(SD: 1.15), compared to 1.76 (SD: 0.9) among hospitals
hosting a urology training program. This is likely ex-
plained by the fact that in academic centers the primary
surgeon is often assisted by resident house staff that
does not require reimbursement by the RAMQ, as op-
posed to community hospitals where 2 or more surgeons
are involved, each billing the RAMQ. It has been re-
ported that logistical difficulties inherent to the add-
itional burden of excess travel time for patients and
physicians and the potential marginalization of lower-
volume hospitals may increase the indirect costs attrib-
utable to surgery in community hospitals [18]. Our
results may be useful in identifying potential geographic
disparities in the cost of BC cancer care.
Given that BC requires patients to undergo labora-
tory tests and invasive procedures for diagnosis, much
of the costs during the management of the disease are
attributed to cystoscopy and TURBT [19]. The frequent
number of these procedures among bladder cancer pa-
tients results in significant cumulative costs [20]. Reim-
bursement for cystoscopy in the USA by Medicare is
approximately 223 $ [8]. Average costs of cystoscopy in
our study (323 $) were higher than some European
countries with similar publically funded health system,
such as Italy (76 $), Germany (61 $), France (51 $), but
considerably lower than UK (620 $) [7]. On the other
hand, average costs of TURBT in Quebec (2159 $)
showed to be similar to these countries (UK: 2154 $;
Germany: 1967 $, France: 1124 $, Italy: 2741 $ and
Belgium: 2201 $) [7]. TURBT represents the first line of
treatment for new tumors and accounts for a substan-
tial portion of total bladder treatment costs [6]. In the
Table 4 Health-care services utilization and total costs
associated with bladder cancer. (Time window: from four
months before radical cystectomy up to 1 year post surgery;
Costs in Canadian dollars)
N (% of the
total study
population)
Total Units Total costs
(Canadian
dollars)
PRE-SURGERY COSTS (n = 2759)
Pre-urologist consultations
(all specialties confounded)
2332 (84.5 %) 9931 2 040 407
Post-urologist consultations
(all specialties confounded)
2155 (78.1 %) 8853 1 906 147
Urologist consultations 2731 (99 %) 10 975 385 244
Cystoscopies 1896 (68.7 %) 2103 577 135
TURBTs 2058 (74.6 %) 2274 4 340 247
Imaging (physician fees) 2532 (91.7 %) 5658 551 684
RADICAL CYSTECTOMY COSTS




2606 (94.5 %) 22 697 1 073 025
Post-operative consultations
(all specialties confounded)
2742 (99.4 %) 81 562 5 594 774
Post-operative medical
oncologist consultations
809 (29.3 %) 7728 406 170
Post-operative imaging
(physician fees)
2535 (92.1 %) 10 716 945 316
Post-operative complications 811 (29.4 %) 2839 4 356 127
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Table 5 Costs associated with bladder cancer stratified by year of surgical procedure. (Time window: from four months before radical cystectomy up to 1 year post surgery;
Costs in Canadian dollars)
Year Number of RC
performed by year









costs per patient by year
Total post-surgery
costs by year
Average total BC costs
per patient by year
Total BC costs
by year
2000 268 19 048 5 104 977 3436 921 024 3908 1 047 425 26 393 7 073 427
2001 281 19 246 5 408 320 3516 988 186 4248 1 193 806 27 011 7 590 313
2002 265 19 284 5 110 398 3296 870 384 4475 1 176 988 27 010 7 157 771
2003 260 19 214 4 995 825 3334 867 014 4752 1 230 848 27 283 7 093 688
2004 289 19 207 5 551 009 3725 1 076 586 5243 1 504 842 28 139 8 132 438
2005 297 19 133 5 682 666 3743 1 108 099 5458 1 621 090 28 322 8 411 856
2006 282 18 833 5 311 004 3708 1 045 657 5938 1 674 592 28 479 8 031 253
2007 282 18 582 5 240 391 3693 1 041 576 5600 1 573 614 27 856 7 855 582
2008 278 18 645 5 183 322 3609 1 003 438 5302 1 463 482 27 518 7 650 243
2009 257 18 615 4 784 141 3717 955 341 3298 827 833 25 553 6 567 317














USA, after accounting for costs of anesthesia and the
operating room, these costs were estimated to be
higher than 2900 $ [21]. Costs at an academic US
medical center ranged from 3000 $ to 6000 $ depend-
ing on patients average hospitalization duration [8]. In
this study, the mean length of stay was 2 days which
contributed to this variation of TURBT costs. In some
centers, patients spend an average of 4 days in the
hospital after a TURBT. One day surgery is common
in Quebec [13, 14].
Surgery for bladder cancer carries a high risk for peri-
operative and post-operative complications with rates
varying from 20 % to 60 % [22, 23]. A recent study con-
ducted by our group estimated that in Quebec postoper-
ative complications occur in 30 % of RC cases [12].
Complications of radical cystectomy prolong the pa-
tient’s length of hospital stay and significantly increase
the total bladder cancer costs [24]. Estimated costs of
complications vary greatly across different studies
according to definitions and categorization of post-
operative complications, and consequently duration of
hospital stay. One of the highest costs attributable to an
adverse event after cystectomy was shown for sepsis in
the USA [25]. In this study, length of stay for patients
with septicemia was estimated at 29 days compared with
10 days for controls. Hospital charges for bacterial infec-
tions was 107 724 $. Average costs for selected post-
operative complications [12] in our study was estimated
at 5703 $, which is lower than other average estimates in
the literature [8]. A great variation in costs was observed
Fig 5 Percentage of each component of cost in the continuum of care for bladder cancer in Quebec
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AB
C
Fig 6 Time series trends in cost per patient (y axis) over time (x axis): (a) Average RC costs; (b) Average post-operative costs; (c) Average total
costs *
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Table 6 Average costs for consultations in September 2009, compared to average forecasted values from ARIMA (1,1,0) model,
and average costs for the study period
Mean and standard deviation
(SD) of costs for September 2009
(Canadian dollars)
Median and range of
costs for September 2009
(Canadian dollars)
Mean and standard deviation
(SD) of costs over all study
period (Canadian dollars)
Median and range of
costs over all study period
(Canadian dollars)
Predicted costs values




Mean: 667 (825) Median: 362 (20–3156) Mean: 1006 (1299) Median: 450 (10–7834) *
Post-urologist consultations
(all specialties confounded)
Mean: 712 (569) Median: 428 (104–3511) Mean: 935 (1038) Median: 523 (6.2-6000) *
Urologist consultations Mean: 127 (85) Median: 129 (16.9-245) Mean: 162 (80) Median: 140 (17–1959) *
Post-operative consultations
(all specialties confounded)
Mean: 453 (345) Median: 261 (64–1724) Mean: 2232 (2275) Median: 1464 (17–27057) *
Post-operative imaging Mean: 139 (326) Median: 90 (31.6-496) Mean: 395 (307) Median: 311 (12.3-2845) *
Post-operative costs Mean: 1384 (589) Median: 278 (57.8-11615) Mean: 4770 (5220) Median: 2759 (33.8-42000) 6559
(95 % CI: 1827–9366)
Total costs Mean: 22223 (19560) Median: 21075 (17341–33249) Mean: 27326 (18652) Median: 25928 (17222–62000) 28224 (95 % CI: 23654–32794)














between hospitals in Quebec with a range of 4109 $ -
7732 $. Similar to what was detected for RC average
costs, community hospitals showed higher average post-
operative complication costs per patients, compared to
academic hospitals. More studies investigating predictors
of higher costs and the impact of cost disparities and its
relation to outcome and survival are needed.
Average total costs per patient in Quebec was found to
be lower than the Canadian province of Ontario (27 388 $
in Quebec versus 33 759 $ in Ontario) [26]. Although we
cannot establish causal relations between medical costs
and patient outcomes based on such ecological data, it is
noteworthy that 5-year overall survival after RC in Quebec
is 46 %, while the rate is 35 % in Ontario [18].
During the study period, total costs of bladder cancer
requiring RC from diagnosis up to one year of follow up
were estimated at more than 70 million dollars, with
more than 70 % of this total expenditure attributed to
health care associated to surgery. Total costs of surgery
and post-operative complications were estimated at 50
million dollars and 4 million dollars, respectively. Total
costs in our cohort represent a small fraction of what
was estimated in the USA for 2010 (3.98 billion dollars,
for all cases confounded) [27]. Reasons for the rising
cost of bladder cancer in the USA are attributable to the
fact that most patients in the US are part of the
Medicare Program [1]. In addition, Medicare reviewed
its reimbursement fees for office-based endoscopic pro-
cedures in 2005, which led to an increased number of
bladder lesions detected and a higher total number of
bladder cancer-related procedures being performed [28].
Total costs estimates in the United Kingdom included
estimates of indirect costs from loss of earnings and
reached 125.2 million in 2010 [29]. Cost of the annual
medical care was estimated to be about 1 million dollars
in Sweden [19] and 27 million dollars in South Korea
[30]. These remarkable variations are due to differences
in both disease incidence and costs of per patient treat-
ment in each national health system. Analyses of specific
explanatory differences in clinical structure or the avail-
ability of resources have not been extensively investi-
gated [1]. A noteworthy result of our study was a
decreasing trend in the average post-operative costs and
total costs caused by a lower average cost for consulta-
tions observed in the year 2009.
To our knowledge, this is the first study to describe
costs attributed to the number of pre and post-
urologist consultations to general practitioners and
other specialists, as well as the costs associated to ur-
ologist consultation during the pre and post-operative
period. Given the paucity of detailed descriptive studies
on the health economics of BC in Canada [26], our
results provide some evidence-based data of interest to
health care providers and policy-makers to better
understand the relationship between resource-
utilization and costs associated with the disease, and to
improve the efficiency and outcomes.
This study had some significant limitations inherent
to the use of administrative databases. We were unable
to measure some factors that can play an important
role on costs of BC requiring RC, such as grade, stage
and severity of the tumor. Data on comorbidity and pa-
tient functional status are also lacking. More import-
antly, since we did not know the actual hospitalization
period for each patient undergoing RC, we could not be
more precise in attributing costs to RC and post-
operative complications. The actual variance of health
services costs is hence, mainly due to the overall differ-
ences in billing codes for physicians’ payments. This in-
formation would be very important in order to
compare costs and efficiencies between administrative
regions, individual hospitals, and surgeons. The imput-
ation of some economic component for medical ser-
vices may have caused some degree of information bias
in the calculation of average costs per patient. Never-
theless, if information bias is present, it is certainly
non-differential, which not undermine internal validity
of our findings. Given that we do not have data on
some medical services such as prescriptions filled by
patients, we could not compare our findings with an
external cohort of patients that would serve as control
group for estimation and comparison of attributable
and net costs. Moreover, considering the intrinsic dis-
crepancies in the management of BC across different
health care systems, we are not convinced that compar-
ing of our findings in the province of Quebec with a
different “control cohort” would decrease the possibility
of information bias.
Also, our study did not account for the burden of in-
direct costs in our analyses, for which we acknowledge
that these costs in the form of patients’ and caregivers’
time, as well as reduced physical and social functioning
contribute to the overall burden of bladder cancer on
society. On the other hand, the fact that the RAMQ is
single-payer and public funded system with universal
healthcare coverage allows the collection of prospective
information for a large sample size, which increases ex-
ternal validity of our findings. The linkage between the
two databases was done using a unique patient identi-
fier, which permitted a very reliable correspondence of
medical services data [31].
Conclusion
Costs of RC surgery, TURBT, medical consultations,
and post-operative complications were the most im-
portant economic components of total bladder cancer
cost per patient requiring radical cystectomy in
Quebec. Significant variations in costs were detected
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between academic and community hospital, as well as
between geo-administrative regions across the province.
More studies are needed to evaluate predictors of costs
and the impact of bladder cancer expenditures on pa-
tient’s clinic outcome and survival.
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